A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903

December 16, 2025 updated by: Risen (Suzhou) Pharma Tech Co., Ltd.

A Phase I/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of Pl3Kα-Selective Inhibitor RP903 (JS105) in Subjects With Advanced Malignancies

This is an open phase I/Ib clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and initial efficacy of RP903 in patients with advanced malignancies who have failed standard treatment or have no standard treatment options. The study was divided into two parts: dose escalation and dose extension (Phase Ia) and clinical extension (Phase Ib).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Phase Ia is divided into two phases of dose escalation and dose extension: This part includes dose escalation and dose extension of RP903 single agent to investigate the safety, tolerability, maximum tolerated dose and pharmacokinetic (PK) characteristics of RP903 single agent.

Phase Ib is the clinical indication expansion phase, and the primary purpose of this phase is to evaluate the initial safety and anti-tumor efficacy in a selected indication target population. After determining RP903 monotherapy RP2D in Phase Ia, SMC will select four advanced malignant tumors with PIK3CA mutations (cervical cancer, endometrial cancer, breast cancer, and ovarian cancer) as indications for clinical expansion studies based on phase Ia efficacy, safety, and pharmacokinetic (PK) data. The dose was determined according to the results of the dose escalation phase and the dose extension phase.

Study Type

Interventional

Enrollment (Actual)

69

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Beijing, China
        • Beijing Cancer Hospital
      • Bengbu, China
        • the First Affiliated Hospital of Bengbu Medical College
      • Changchun, China
        • Jilin cancer hospital
      • Changchun, China
        • Jilin University First Hospital
      • Chengdu, China
        • Sichuan Cancer Hospital
      • Chongqing, China
        • Chongqing University Cancer Hospital
      • Fuzhou, China
        • Fujian Medical University Union Hospital
      • Fuzhou, China
        • Fujian Cancer Hospital
      • Hangzhou, China
        • Zhejiang Cancer Hospital
      • Hangzhou, China
        • Sir Run Run Shaw Hospital
      • Harbin, China
        • Harbin Medical University Cancer Hospital
      • Jinan, China
        • Shandong Cancer hospital & institute
      • Jining, China
        • Affiliated Hospital of Jining Medical College
      • Linyi, China
        • Linyi Cancer Hospital
      • Luoyang, China
        • The First Affiliated Hospital of Henan University of Science and Technology
      • Nanning, China
        • Guangxi Medical University Cancer Hospital
      • Qingdao, China
        • The Affiliated Hospital of Qingdao University
      • Shanghai, China
        • Affiliated Cancer Hospital of Fudan University
      • Shenyang, China
        • LiaoNing Cancer Hospital&Institute
      • Suining, China
        • Suining Central Hospital
      • Wuhan, China
        • Hubei Cancer Hospital
      • Yinchuan, China
        • Ceneral Hosipital of Ningxia Medical University
      • Zhengzhou, China
        • Henan Cancer Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Agreement to provide fresh or archived tumor tissue sample within 3 years
  • Ia (dose escalation phase and dose expansion phase):patients with pathologically confirmed advanced Malignant solid tumour who have experienced Treatment failure, are unable to tolerate standard treatment, or have no standard treatment
  • Ib: Patients with advanced malignant solid tumours who have PIK3CA activating mutations, experience treatment failure, are intolerant to standard treatment, or have no standard treatment
  • Phase Ia: Solid tumour, not limited to specific types; dose expansion phase will prioritize cervix carcinoma, endometrial cancer, ovarian cancer, and breast cancer.
  • Phase Ib:Cervix carcinoma (Expanded Cohort 1):Having received first-line (including Platinum-based chemotherapy ± bevacizumab) or second-line treatment and having disease progression during or after treatment; (recurrence during or within 12 months after neoadjuvant or adjuvant treatment in previous treatment will be regarded as one treatment line)
  • Phase Ib:Endometrial cancer (extension cohort 2):Progression during or after first-line (including platinum) or second-line treatment of advanced or metastatic disease; (recurrence during or within 12 months after neoadjuvant or adjuvant treatment in previous treatment will be considered as one treatment line);Sarcoma type not included
  • Ovarian cancer (expanded cohort 3) (PIK3CA mutation):
  • Ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma who have experienced treatment failure or are intolerant to at least one line of cytotoxic therapy ± PARP inhibitor; (recurrence during or within 12 months after neoadjuvant or adjuvant therapy will be considered one line of therapy)
  • Pathological types include high-grade serous carcinoma, clear cell carcinoma, or Endometrioid carcinoma
  • Breast cancer (extension cohort 4) (PIK3CA mutation):
  • Advanced, recurrent and metastatic breast cancer;
  • Prior systemic treatment in at least 1 line and no more than 3 lines (patients who have relapsed during or within 12 months after completion of neoadjuvant/adjuvant endocrine therapy will be considered as one line of endocrine therapy)
  • At least one measurable lesion as per RECIST v1.1 (except the dose-escalation phase of monotherapy)
  • Eastern Cooperative Oncology Group (ECOG) performance status score: 0-1
  • Adequate hematologic and organ function

Exclusion Criteria:

  • Patients with known allergy to any component of RP903
  • Previously treated with PI3K, mTOR or AKT inhibitors
  • Systemic anti-tumor therapy within 4 weeks prior to the first dose
  • Presence of leptomeningeal or meningeal metastasis, or presence of signs of carcinomatous Meningitis
  • Metastases to bone marrow
  • Child-Pugh grade B or C
  • Active hepatitis B or C
  • History of type I Diabetes mellitus,gestational diabetes or uncontrolled type II Diabetes mellitus

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: RP903 arm
Ia:Participants will receive RP903 in escalating dose levels with starting dose of 50mg, po qd for each 28-day cycle Ib:Participants will receive RP903 with RP2D, po qd for each 28-day cycle
Ia:RP903 50mg, 100mg, 200mg, 300mg,350mg,or other dose, po qd for each 28-day cycle; Ib: RP903,RP2D,po qd for each 28-day cycle

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ia:dose-limiting toxicity(DLTs)
Time Frame: 28 days
Incidence and severity of dose-limiting toxicity (DLTs)
28 days
Ia:Adverse Events
Time Frame: 2 years
Incidence and severity of Adverse Events(AEs) according to NCI-CTCAE
2 years
Ia: serious adverse events
Time Frame: 2 years
Incidence and severity of serious adverse events(SAEs) according to NCI-CTCAE
2 years
Ia: Abnormal changes in Laboratory test and other abnormalities
Time Frame: 2 years
Incidence and severity of abnormal changes in Laboratory test and other tests with clinically significant according to NCI-CTCAE
2 years
Ia: MTD
Time Frame: 2 years
Maximum Tolerated Dose(MTD)
2 years
Ia: MAD
Time Frame: 2 years
Maximum Administrated Dose(MAD)
2 years
Ia:RP2D
Time Frame: 2 years
Recommended Phase II Dose(RP2D)
2 years
Ib:objective response rate(ORR);
Time Frame: 2 years
Efficacy evaluated by the investigator according to RECIST v1.1: objective response rate (ORR);
2 years
Ib:AE
Time Frame: 2 years
Type, frequency, duration, severity and characteristics of Adverse Events (AEs) according to NCI-CTCAE
2 years
Ib:SAE
Time Frame: 2 years
Type, frequency, duration, severity and characteristics of serious adverse events(SAEs) according to NCI-CTCAE
2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ia:the concentration of RP903 or its metabolites (if applicable)
Time Frame: 1 years
the concentration of RP903 or its metabolites (if applicable) in individual subjects at different time points after administration;
1 years
Ia:Cmax
Time Frame: 1 years
peak concentration
1 years
Ia:Ctrough
Time Frame: 1 years
trough concentration
1 years
Ia:Tmax
Time Frame: 1 years
time to peak
1 years
Ia:AUC0-t and AUC0-∞
Time Frame: 1 years
area under the plasma drug concentration-time curve
1 years
Ia:Vd/F
Time Frame: 1 years
distribution volume
1 years
Ia:CL/F
Time Frame: 1 years
clearance
1 years
Ia:t1/2
Time Frame: 1 years
half-life
1 years
Ia:Rac
Time Frame: 1 years
cumulative factor
1 years
Ia:ORR
Time Frame: 1 years
objective response rate
1 years
Ia:DoR
Time Frame: 1 years
duration of response
1 years
Ia:DCR
Time Frame: 1 years
disease control rate
1 years
Ia:TTR
Time Frame: 1 years
time to response
1 years
Ia:PFS
Time Frame: 1 years
progression-free survival
1 years
Ia:OS
Time Frame: 1 years
overall survival
1 years
Ib:safety:AE
Time Frame: 2 years
Type, frequency, duration, severity and characteristics of serious adverse events(SAEs) according to NCI-CTCAE
2 years
Ib:safety:SAE
Time Frame: 2 years
Type, frequency, duration, severity and characteristics of serious adverse events(SAEs) according to NCI-CTCAE
2 years
Ib:safety:Body temperature
Time Frame: 2 years
Body temperature changes according to NCI-CTCAE
2 years
Ib:safety:pulse
Time Frame: 2 years
pulse changes according to NCI-CTCAE
2 years
Ib:safety:respiratory rate
Time Frame: 2 years
respiratory rate changes according to NCI-CTCAE
2 years
Ib:safety: blood pressure
Time Frame: 2 years
blood pressure changes according to NCI-CTCAE
2 years
Ib:safety:laboratory test
Time Frame: 2 years
laboratory test changes according to NCI-CTCAE
2 years
Ib:safety:heart rate
Time Frame: 2 years
heart rate changes according to NCI-CTCAE
2 years
Ib:safety:QT
Time Frame: 2 years
QT changes according to NCI-CTCAE
2 years
Ib:safety:QTcF
Time Frame: 2 years
QTcF changes according to NCI-CTCAE
2 years
Ib:safety:PR
Time Frame: 2 years
PR changes according to NCI-CTCAE
2 years
Ib:DoR
Time Frame: 1 years
duration of response
1 years
Ib:DCR
Time Frame: 1 years
disease control rate
1 years
Ib:TTR
Time Frame: 1 years
time to response
1 years
Ib:PFS
Time Frame: 1 years
progression-free survival
1 years
Ib:OS
Time Frame: 2 years
overall survival
2 years
Ib:Concentrations of RP903 or its metabolites
Time Frame: 1 years
Concentrations of RP903 or its metabolites (if applicable) in individual subjects at different time points after dosing.
1 years

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
blood glucose
Time Frame: 28days
To explore the relationship between blood glucose levels in peripheral blood and efficacy;
28days
Insulin
Time Frame: 28days
To explore the relationship between Insulin levels in peripheral blood and efficacy;
28days
C-peptide
Time Frame: 28days
To explore the relationship between C-peptide levels in peripheral blood and efficacy;
28days
PIK3CA mutation status
Time Frame: 28days
To explore the correlation between peripheral blood and tumor tissue PIK3CA mutation status in different indications;
28days
peripheral blood PIK3CA mutation
Time Frame: 28days
To explore the correlation between peripheral blood PIK3CA mutation and efficacy;
28days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 7, 2022

Primary Completion (Actual)

May 30, 2025

Study Completion (Actual)

May 30, 2025

Study Registration Dates

First Submitted

January 19, 2025

First Submitted That Met QC Criteria

February 20, 2025

First Posted (Actual)

February 25, 2025

Study Record Updates

Last Update Posted (Actual)

December 23, 2025

Last Update Submitted That Met QC Criteria

December 16, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • JS105-001-I

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.